
    
      The study is a randomized interventional comparative Phase III trial. The duration of the
      trial for each subject is expected to be 3 months. The duration for each individual subject
      includes one-month study treatment and 3 months follow-up time. Recruitment of subjects will
      start in April 2020.

      150 adult male and female patients with positive COVID-19 diagnosis and fulfilling the below
      outlined inclusion criteria will be enrolled into the study. Trial population will consist of
      both genders.

      Name of tested drug: Isotretinoin. All consenting adult patients having confirmed COVID-19
      will be recruited and randomly and blindly allocated in a 1:1:1 ratio to the following arms:

      Group (1): 50 patients will receive isotretinoin 0.5 mg/kg/day for one month or until viral
      clearance.

      Group (2): 50 patients will receive standard therapy for COVID-19 (Paracetamol 500 mg /6h,
      Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first
      day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid
      500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2
      capsules twice daily in severe cases).

      Group (3): 50 patients will receive standard therapy for COVID-19 + isotretinoin 0.25
      mg/kg/day for one month or until viral clearance.

      Inclusion Criteria:

        -  Clinical and laboratory diagnosis of COVID-19.

        -  Age range 18-40

      Exclusion Criteria:

      • Have the following conditions:

        1. Hypercholesterolemia

        2. Hypertriglyceridemia

        3. Liver disease

        4. Renal disease

        5. Sjögren syndrome

        6. Pregnancy

        7. Lactation

        8. Depressive disorder

        9. Contraindications for hormonal contraception or intrauterine device.
    
  